AI health tech Respiree closes $11.6m Series A

Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, has announced the successful closing of an $11.6 million Series A financing round, led by We Venture Capital and ClavystBio, with participation from Adaptive Capital Partners also.

Respiree’s innovative, augmented-AI platform seeks to support quicker, efficient, and precise decision making in various healthcare settings by automating patient monitoring, care pathway management, and clinical insight delivery. One of its flagship AI models developed during the Mayo Clinic Platform Accelerate programme, where Respiree graduated from, can help healthcare professionals detect patient deterioration earlier – including rapid response calls in general wards and unplanned ICU transfers.

Published as a pre-print in The Lancet, Respiree’s flagship AI model significantly reduced false alarms while maintaining strong sensitivity – outperforming the positive predictive value (PPV) of EPIC’s deterioration index by a factor of six (54.9% vs 8%).

Proceeds from the financing round will support expansion of Respiree’s commercial team and US presence, including company headquarters in Houston, Texas, at the Texas Medical Center (TMC) Innovation.

Respiree is currently in the process of seeking clearance from the US Food and Drug Administration (FDA) for this flagship AI model, with the goal of integrating it into its platform, 1Bio, which already incorporates data from electronic health records (EHRs), mobile questionnaires, third party devices, and Respiree’s proprietary, US-patented, FDA-cleared sensors to provide longitudinal insights into disease trajectories.

Dr Gurpreet Singh, founder and CEO of Respiree, commented on the funding round: “The digitalisation of healthcare offers a powerful opportunity to improve outcomes and efficiency – but without the right tools, it risks overwhelming care systems, especially amid workforce shortages.”

Singh added: “What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality. We're now focused on scaling these tools to enhance the entire patient journey – from smarter triage to follow-up.”

Louise Warme, head of We Venture Capital, said: “We are very proud to welcome Respiree to the We VC portfolio. [It] stands out in the market by providing a patient monitoring AI/ML + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration.”

Meanwhile, Anselm Tan, ClavystBio’s digital health & medtech lead, commented: “ClavystBio’s investment in Respiree is central to our strategy of helping companies scale globally from and through Singapore. Their innovative AI-powered monitoring platform is set to enhance patient care and empower clinical teams with actionable insights.”

Founded in Singapore, Respiree is now executing its global strategy to expand into new markets worldwide. The company’s solutions are currently available in the US, Australia, and across Asia-Pacific (APAC), and Respiree recently announced a partnership with Roche Diagnostics to launch pilot programmes across the APAC region.

A portion of the Series A funds will be used to strengthen operations with existing channel partners and accelerate the development of new business relationships. Respiree plans to expand its offerings into newer international markets including the Gulf Cooperation Council and Thailand.